Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

77 patients with chronic active or persistent hepatitis of type B proved by liver biopsy were divided into two groups. 39 cases were treated with Ara-A. dauricine and polysaccharide of pore umbellate as group I. 38 cases were treated with Ara-A, radix isatidis and radix salviae mitiorrhize as group II. By the end of 3 months in the course, the effective rates of ALT and AST were 68.6% and 68.4% in group I, 34.4% and 34.8% in group II. The rates of HBeAg from positive to negative were 35.9% and 39.5% in group I and II respectively. Follow up to 3 months after cessation of therapy, ALT level was normal in 55.6% of group I and 60% of group II: HBeAg was negative in 42.9% of group I and in 50% of group II. Follow up to 9 months after cessation of the treatment, ALT was normal in 56.3% of group I and in 62.5% of group II, HBeAg was negative in 37.5% of group I and in 60% of group II. These results show that dauricine and polysaccharide of pore umbellate did not strengthen the antiviral effect of Ara-A.
 ...
PMID:[Therapeutic effect of combined treatment with Ara-A dauricine and Chinese herbs in chronic hepatitis B infection]. 179 48

A considerable amount of information has accumulated during the past 10 years in the search for antiviral agents. Ribavirin and inosiplex are 2 interesting developments to come out of this search. Ribavirin, a synthetic nucleoside, has an unusually wide spectrum of antiviral activity, especially when tested in vitro. A large number of RNA and DNA viruses are sensitive, especially herpes viruses, poxvirus, influenza, parainfluenza, reovirus, togavirus, and RNA tumour viruses. The in vivo antiviral spectrum of activity is much narrower, with activity against herpes virus, influenza, parainfluenza, measles and adenoviruses. However, controlled clinical trials have not been uniformly successful in treating influenza, hepatitis, herpes simplex and herpes zoster. Inosiplex has been shown to have antiviral activity in vivo against influenza, herpes simplex, rhinovirus and vaccinia virus infections. However, antiviral activity has not been consistently demonstrated, and this observation led to further studies which revealed its immunomodulating effects. The accumulated evidence has indicated that inosiplex is more a prohost agent rather than an antiviral drug. Immune functions which are depressed during viral infection can be restored to normal by inosiplex therapy. At present, neither ribavirin nor inosiplex alone has been shown to be uniformly successful in the treatment of human viral diseases. Nevertheless, their potential place in chemotherapy should not be neglected, although further data are needed to determine what this place will be. Whether combining them with other antiviral agents such as interferon, acyclovir, Ara-A, and so on, would produce a potentiation of action and improved antiviral chemotherapy, will be an interesting area for further study.
 ...
PMID:Ribavirin and inosiplex: a review of their present status in viral diseases. 616 18

To preliminarily observe the antiviral effect of receptor-targeted drug, the Lactosaminated Human Serum Albumin Arabinoside Adenine Monophosphate (L-HSA-Ara-AMP), 10 patients with chronic type B hepatitis (HBsAg, HbeAg/HBV DNA positive) were treated with this drug for 5 days. The daily dose of L-HSA-Ara-AMP was 35 mg/Kg (containing 1.5 mg Ara-AMP), whereas the usual daily dose of free Ara-AMP is 10 mg/Kg. In 10 patients treated, three patients' HBeAg became negative and six patients' HBeAg titer fell. Anti-HBc IgM all became negative in 4 anti-HBc IgM positive patients. In 8 HBV DNA positive patients, four patients' HBV DNA became negative and the other four patients' HBV DNA decreased. HBsAg remained positive in all of the ten patients. No adverse effects were observed. The results showed that L-HSA-Ara-AMP inhibits HBV as effective as free Ara-AMP, but at a daily dose 6.7 times lower than free Ara-AMP.
 ...
PMID:[Preliminary clinic observation on the inhibition of HBV by receptor-targeted drug L-HSA-AraAMP]. 1251 62

Up to now Interferon (IFN) has been the only licensed treatment for chronic type B and D viral hepatitis. However, IFN monotherapy is efficacious only in HBeAg positive chronic hepatitis B and is aggravated by important side effects in many patients. To overcome the limits of IFN monotherapy, combination therapies of this cytokine together with other synergistic drugs have been proposed and many antivirals that directly act on Hepatitis B Virus (HBV) synthesis have been developed. Combination therapies with acyclovir, levamisole, and cortisone have not been more advantageous than IFN alone. Of the antivirals, Adenine Arabinoside monophosphate, though active against HBV, causes severe neurotoxicity and Famciclovir has not shown significant efficacy in a large multicenter study of chronic HBeAg positive hepatitis. Lamivudine appears the most promising in terms of clinical benefit, safety and tolerance. It is active on wild type HBV as well as on HBeAg-minus variants of the virus. However, although HBV is consistently repressed while on therapy, only a part of the patients are cured or remain in remission after Lamivudine withdrawal. Maintenance therapy is in order, but the long-term use of Lamivudine is complicated by the emergence of polymerase gene-mutants which may recapitulate disease. Combination with other antivirals active also against Lamivudine escape mutants opens promising new prospects. There is as yet no valid therapy for chronic HDV hepatitis; IFN is of no benefit in most cases.
 ...
PMID:Therapy for chronic hepatitis B. Present status. 1649 43